MIM
AXDX

MetLife Investment Management’s Accelerate Diagnostics AXDX Stock Holding History

MetLife Investment Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,469
Closed -$157K – 2275
2020
Q3 		$157K Hold
1,469
– – ﹤0.01% 2004
2020
Q2 		$223K Buy
1,469
+346
+31% +$34.1K ﹤0.01% 1846
2020
Q1 		$93.5K Hold
1,123
– – ﹤0.01% 2110
2019
Q4 		$190K Hold
1,123
– – ﹤0.01% 2005
2019
Q3 		$208K Sell
1,123
-442
-28% -$85.4K ﹤0.01% 1922
2019
Q2 		$358K Buy
1,565
+430
+38% +$84.1K ﹤0.01% 1685
2019
Q1 		$239K Hold
1,135
– – ﹤0.01% 1886
2018
Q4 		$131K Hold
1,135
– – ﹤0.01% 2157
2018
Q3 		$260K Hold
1,135
– – ﹤0.01% 1940
2018
Q2 		$253K Hold
1,135
– – ﹤0.01% 1806
2018
Q1 		$259K Hold
1,135
– – ﹤0.01% 1754
2017
Q4 		$297K Buy
+1,135
New +$266K ﹤0.01% 1716

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

MetLife Investment Management's AXDX Position: Q4 2020 in Review

MetLife Investment Management sold out of Accelerate Diagnostics (AXDX) in Q4 2020, closing a stake of 1,469 shares — an estimated $157K sold.

MetLife Investment Management first reported a position in AXDX in Q4 2017 and held it in 12 quarters. The position peaked at $358K in Q2 2019. 115 funds tracked by Wall St. Rank hold AXDX as of Q4 2020.

  • MetLife Investment Management reported no remaining Accelerate Diagnostics position as of Q4 2020 after selling out during the quarter.
  • MetLife Investment Management sold 1,469 Accelerate Diagnostics shares in Q4 2020, an estimated $157K.
  • MetLife Investment Management first reported a position in Accelerate Diagnostics in Q4 2017 and held it in 12 quarters.
  • MetLife Investment Management's Accelerate Diagnostics position peaked at $358K in Q2 2019.
  • 115 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2020.

Based on MetLife Investment Management's 13F filing for Q4 2020, filed 16 Feb 2021.